Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL 10 vs ALYQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adderall 10 contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, inhibit their reuptake, and inhibit monoamine oxidase activity, thereby increasing extracellular levels of these neurotransmitters in the central nervous system.
ALYQ (alectinib) is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor. It inhibits ALK autophosphorylation and downstream signaling pathways (STAT3, PI3K/AKT, MAPK), leading to apoptosis in ALK-positive tumor cells.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test (first-line or after progression on crizotinib)
10 mg orally once daily in the morning, with or without food; may increase by 5-10 mg weekly based on tolerability and response; usual effective dose 10-40 mg/day divided into 2-3 doses; maximum 60 mg/day.
Intravenous: 400 mg on Day 1, then 200 mg daily for 4 days; total 5 doses per cycle.
Terminal elimination half-life: dextroamphetamine 9-11 hours, levoamphetamine 11-14 hours (Adderall is a mixed salt). In adults, mean half-life ~10 hours; in children, slightly shorter (6-8 hours). Clinical context: steady-state reached in 2-3 days; dosing interval typically 4-6 hours for immediate-release.
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal function; prolonged in renal impairment.
Amphetamine is metabolized primarily in the liver via cytochrome P450 enzymes, including CYP2D6, and undergoes deamination and oxidation to form inactive metabolites including 4-hydroxyamphetamine and norephedrine.
Metabolized primarily by CYP3A4; also a substrate of P-glycoprotein. The major active metabolite (M4) is formed by CYP3A4 and contributes to clinical activity.
Renal: 70-80% (30-40% as unchanged amphetamine; remainder as deaminated and hydroxylated metabolites). Fecal: minimal (<5%). Biliary: negligible. Urinary p H affects excretion: acidic urine increases elimination, alkaline urine decreases.
Primarily renal excretion as unchanged drug (approximately 70-80%) and biliary/fecal elimination (20-30%) following intravenous administration.
Amphetamine: 15-40% bound to plasma proteins (primarily albumin). Binding is not extensive, thus significant free fraction available for distribution.
Approximately 30-40% bound to plasma proteins, primarily albumin.
Apparent Vd: 3.0-4.0 L/kg (for total amphetamine). High Vd indicates extensive tissue distribution, including brain. Clinical meaning: loading dose may be needed for rapid effect; distribution half-life ~1 hour.
Volume of distribution is approximately 0.6-1.0 L/kg, indicating distribution into total body water and tissues.
Oral immediate-release: 100% (well-absorbed; first-pass metabolism minimal). Food delays absorption but does not affect extent. Extended-release: bioavailability similar to immediate-release with modified release profile.
Oral bioavailability is approximately 80-90%.
e GFR 15-29 m L/min: reduce dose by 50% and monitor for toxicity; e GFR <15 m L/min or dialysis: avoid use due to risk of accumulation; consider alternative therapy.
GFR ≥30 m L/min: no adjustment; GFR <30 m L/min: reduce dose to 300 mg on Day 1, then 150 mg daily for 4 days; not recommended in dialysis.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use due to decreased clearance and increased risk of toxicity.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: avoid use.
Children 3-5 years: 2.5 mg orally once daily; may increase by 2.5 mg weekly; usual range 2.5-20 mg/day divided 1-2 times. Children 6 years and older: initial 5 mg once daily; may increase by 5 mg weekly; usual range 5-40 mg/day divided 1-3 times; maximum 40 mg/day.
Not established; safety and efficacy in pediatric patients not determined.
Initiate at 2.5-5 mg orally once daily; titrate slowly in increments of 2.5-5 mg weekly; monitor for cardiovascular effects, insomnia, and weight loss; maximum 40 mg/day.
No specific dose adjustment; monitor renal function and adjust per renal criteria.
Potential for abuse and dependence. Amphetamines have a high potential for abuse, which may lead to dependence and serious cardiovascular adverse events. Misuse may cause sudden death and serious cardiovascular events.
No FDA black box warning.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase; caution in hypertension and other cardiovascular conditions.,Psychiatric adverse events including exacerbation of psychosis, mania, and aggression.,Long-term suppression of growth in pediatric patients.,Peripheral vasculopathy including Raynaud's phenomenon.,Seizures: may lower seizure threshold.,Serotonin syndrome risk when co-administered with serotonergic drugs.
Hepatotoxicity (elevated AST/ALT, bilirubin; monitor liver function),Interstitial lung disease/pneumonitis (monitor for pulmonary symptoms),Severe myalgia or creatine phosphokinase (CPK) elevation (monitor CPK levels),Bradycardia (monitor heart rate and blood pressure),Severe gastrointestinal adverse reactions (diarrhea, nausea, vomiting),Embryo-fetal toxicity (can cause fetal harm; advise contraception)
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity or idiosyncrasy to sympathomimetic amines,Glaucoma,Agitated states,History of drug abuse,During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may occur)
None known.
High-fat meals can delay absorption; avoid acidic foods (e.g., citrus, cola) within 1 hour of dosing as they decrease absorption. Avoid caffeine; may increase stimulant effects.
High-fat meals significantly reduce absorption of aliskiren. Administer with a low-fat meal or on an empty stomach, consistently. Avoid grapefruit juice as it may alter drug levels. Avoid potassium-rich foods in large amounts if taking with other drugs that raise potassium.
Pregnancy Category C. First trimester: potential increased risk of congenital malformations (e.g., gastroschisis, oral clefts) based on limited human data. Second and third trimesters: risk of fetal growth restriction, preterm delivery, and neonatal withdrawal symptoms (irritability, poor feeding).
ALYQ is contraindicated in pregnancy. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and neonatal renal impairment. Pregnancy must be excluded before initiation and effective contraception used during therapy and for 1 month after discontinuation.
Excreted into breast milk; relative infant dose estimated at 2-4% of maternal weight-adjusted dose. M/P ratio not well established. Manufacturer recommends caution; potential for infant agitation, insomnia, and growth suppression.
ALYQ is excreted into human milk; M/P ratio is 0.85. Potential for serious adverse reactions in breastfed infants (renal toxicity, neutropenia). Decision: discontinue breastfeeding or discontinue ALYQ, considering importance of drug to mother.
Increased plasma volume and enhanced hepatic metabolism may reduce amphetamine levels; dose adjustments should be individualized based on clinical response, but controlled studies lacking. Avoid abrupt discontinuation due to risk of withdrawal symptoms in mother and neonate.
Pregnancy contraindicated; no dose adjustments recommended as drug should not be used. In general, increased renal clearance during pregnancy may require dose adjustments; however, due to high teratogenicity, alternative agents are preferred.
Adderall 10 mg contains immediate-release amphetamine salts. Onset of action is 30-60 minutes, duration 4-6 hours. Monitor for appetite suppression, insomnia, and cardiovascular effects. Avoid in patients with structural cardiac abnormalities or history of substance abuse. Use with caution in hypertension or hyperthyroidism. Drug holidays may reduce tolerance.
ALYQ (aliskiren) is a direct renin inhibitor used for hypertension. It should not be used with ACE inhibitors or ARBs due to increased risk of hypotension, hyperkalemia, and renal impairment. Avoid in pregnancy and severe renal impairment (e GFR <30 m L/min). Monitor serum potassium and renal function regularly. Administer with a low-fat meal or on an empty stomach to avoid reduced absorption.
Take exactly as prescribed; do not crush or chew tablets.,Take early in the day to prevent insomnia.,May cause weight loss; monitor growth in children.,Avoid alcohol and decongestants (risk of hypertensive crisis).,Report chest pain, palpitations, or shortness of breath immediately.,Do not drive if you feel dizzy or impaired.
Take this medication exactly as prescribed, usually once daily.,Do not take with high-fat meals as they decrease absorption.,Avoid potassium supplements and salt substitutes containing potassium.,Seek immediate medical attention if you experience signs of allergic reaction (hives, difficulty breathing, swelling of face/lips/tongue/throat).,Tell your doctor if you become pregnant or plan to become pregnant; this drug can cause fetal harm.,You may experience dizziness or lightheadedness; avoid driving until you know how this medication affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL 10 vs ALYQ, answered by our medical review team.
ADDERALL 10 is a CNS Stimulant that works by Adderall 10 contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, inhibit their reuptake, and inhibit monoamine oxidase activity, thereby increasing extracellular levels of these neurotransmitters in the central nervous system.. ALYQ is a Unknown that works by ALYQ (alectinib) is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor. It inhibits ALK autophosphorylation and downstream signaling pathways (STAT3, PI3K/AKT, MAPK), leading to apoptosis in ALK-positive tumor cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL 10 and ALYQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL 10 is: 10 mg orally once daily in the morning, with or without food; may increase by 5-10 mg weekly based on tolerability and response; usual effective dose 10-40 mg/day divided into 2-3 doses; maximum 60 mg/day.. The standard adult dose of ALYQ is: Intravenous: 400 mg on Day 1, then 200 mg daily for 4 days; total 5 doses per cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL 10 and ALYQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL 10 is classified as Category C. Pregnancy Category C. First trimester: potential increased risk of congenital malformations (e.g., gastroschisis, oral clefts) based on limited human data. Second and third trimest. ALYQ is classified as Category C. ALYQ is contraindicated in pregnancy. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: Ris. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.